Quantitative perfusion and water transport time model from multi b-value diffusion magnetic resonance imaging validated against neutron capture microspheres.

Intravoxel Incoherent Motion (IVIM) is a non-contrast magnetic resonance imaging diffusion-based scan that uses a multitude of b-values to measure various speeds of molecular perfusion and diffusion, sidestepping inaccuracy of arterial input functions or bolus kinetics in quantitative imaging. We test a new method of IVIM quantification and compare our values to reference standard neutron capture microspheres across normocapnia, CO2 induced hypercapnia, and middle cerebral artery occlusion in a controlled animal model. Perfusion quantification in ml/100g/min compared to microsphere perfusion uses the 3D gaussian probability distribution and defined water transport time as when 50% of the molecules remain in the tissue of interest. Perfusion, water transport time, and infarct volume was compared to reference standards. Simulations were studied to suppress non-specific cerebrospinal fluid (CSF). Linear regression analysis of quantitative perfusion returned correlation (slope = .55, intercept = 52.5, $R^2$= .64). Linear regression for water transport time asymmetry in infarcted tissue was excellent (slope = .59, intercept = .3, $R^2$ = .93). Strong linear agreement also was found for infarct volume (slope = 1.01, $R^2$= .79). Simulation of CSF suppression via inversion recovery returned blood signal reduced by 82% from combined T1 and T2 effects. Intra-physiologic state comparison of perfusion shows potential partial volume effects which require further study especially in disease states. The accuracy and sensitivity of IVIM provides evidence that observed signal changes reflect cytotoxic edema and tissue perfusion. Partial volume contamination of CSF may be better removed during post-processing rather than with inversion recovery to avoid artificial loss of blood signal.

Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.

BACKGROUND: Convalescent plasma therapy for COVID-19 relies on transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial. METHODS: Multivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed-effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19. RESULTS: Donor antibody titres ranged from 0 to 1 : 3892 (anti-receptor binding domain (RBD)) and 0 to 1 : 3289 (anti-spike). Higher anti-RBD and anti-spike titres were associated with increased age, hospitalization for COVID-19, fever and absence of myalgia (all P < 0.05). Fatigue was significantly associated with anti-RBD (P = 0.03). In pairwise comparison amongst ABO blood types, AB donors had higher anti-RBD and anti-spike than O donors (P < 0.05). No toxicity was associated with plasma transfusion. Non-ECMO recipient anti-RBD antibody titre increased on average 31% per day during the first three days post-transfusion (P = 0.01) and anti-spike antibody titre by 40.3% (P = 0.02). CONCLUSION: Advanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titre to COVID-19. Despite variability in donor titre, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion amongst COVID-19-infected patients is needed.

New insecticides for management of tomato yellow leaf curl, a virus vectored by the silverleaf whitefly, Bemisia tabaci.

Greenhouse studies using a randomized complete block design were carried out to evaluate the effect of six insecticides on transmission of Tomato yellow leaf curl virus (TYLCV) by the silverleaf whitefly, Bemisia tabaci biotype B Gennadius (Hemiptera: Aleyrodidae) to tomato, Lycopersicon esculentum (Miller) (Solanales: Solanaceae), seedlings that were inoculated with whiteflies from a TYLCV colony in cages 3, 7, or 14 d after treatment with insecticide. The purpose was to reveal differences in residual efficacy of four materials that are nearing registration for use on tomato-cyazypyr, flupyradifurone, pyrafluquinazon, and sulfoxaflor-and to compare them with two established insecticides, pymetrozine and a zeta-cypermethrin/bifenthrin combination. Differences in efficacy were expected because these six materials represent five distinct modes of action and both contact and systemic materials. Percentage of tomato seedlings expressing virus symptoms tended to be lowest in seedlings treated with flupyradifurone. The zeta-cypermethrin/bifenthrin insecticide demonstrated comparable efficacy to flupyradifurone in some trials at 3 and 7 d after treatment inoculations, but not the 14 d after treatment inoculation. Pyrafluquinazon was not statistically different from cyazypyr or sulfoxaflor in percentage of plants with virus symptoms in any trial. Percentage virus in the cyazypyr and sulfoxaflor treatments was not statistically different in the 3 and 7 d after treatment inoculations. Among seedlings treated with insecticide, percentage with virus symptoms tended to be highest in the seedlings treated with pymetrozine.